BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 29215037)

  • 21. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer.
    He W; Yin C; Guo G; Jiang C; Wang F; Qiu H; Chen X; Rong R; Zhang B; Xia L
    Med Oncol; 2013 Mar; 30(1):439. PubMed ID: 23307251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?
    Solmaz Medeni S; Acar C; Olgun A; Acar A; Seyhanlı A; Taskıran E; Sevindik OG; Alacacıoglu I; Piskin O; Ozcan MA; Demirkan F; Undar B; Ozsan GH
    Clin Transplant; 2018 Sep; 32(9):e13359. PubMed ID: 30053318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer.
    Matsuda A; Yamada T; Matsumoto S; Sakurazawa N; Kawano Y; Shinozuka E; Sekiguchi K; Suzuki H; Yoshida H
    Anticancer Res; 2019 Aug; 39(8):4343-4350. PubMed ID: 31366528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma.
    Feng X; Li L; Wu J; Zhang L; Sun Z; Li X; Wang X; Yu H; Chang Y; Wu X; Zhou Z; Wang G; Li W; Li Z; Zhang X; Zhang M
    Oncologist; 2019 Nov; 24(11):e1123-e1131. PubMed ID: 30952822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative Neutrophil-to-Lymphocyte Ratio is a Better Prognostic Serum Biomarker than Platelet-to-Lymphocyte Ratio in Patients Undergoing Resection for Nonmetastatic Colorectal Cancer.
    Choi WJ; Cleghorn MC; Jiang H; Jackson TD; Okrainec A; Quereshy FA
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S603-13. PubMed ID: 25900206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy.
    Jiang J; Ma T; Xi W; Yang C; Wu J; Zhou C; Wang N; Zhu Z; Zhang J
    Cancer Manag Res; 2019; 11():8657-8668. PubMed ID: 31576170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The preoperative neutrophil to lymphocyte ratio is a superior indicator of prognosis compared with other inflammatory biomarkers in resectable colorectal cancer.
    Song Y; Yang Y; Gao P; Chen X; Yu D; Xu Y; Zhao J; Wang Z
    BMC Cancer; 2017 Nov; 17(1):744. PubMed ID: 29126400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab.
    Kuramochi H; Yamada T; Yoshida Y; Matsuda A; Kamiyama H; Kosugi C; Ishibashi K; Fukazawa A; Ihara K; Sonoda H; Yoshimatsu K; Yoshida H; Hasegawa S; Sakamoto K; Ishida H; Koda K;
    Anticancer Res; 2021 Jun; 41(6):3131-3137. PubMed ID: 34083307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic immune response in squamous cell carcinoma of the head and neck: a comparative concordance index analysis.
    Tham T; Wotman M; Chung C; Ahn S; Dupuis H; Gliagias V; Movsesova T; Kraus D; Costantino P
    Eur Arch Otorhinolaryngol; 2019 Oct; 276(10):2913-2922. PubMed ID: 31312922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation.
    Chu MO; Shen CH; Chang TS; Xu HW; Yen CW; Lu SN; Hung CH
    Sci Rep; 2018 Nov; 8(1):16611. PubMed ID: 30413724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
    Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Pietrantonio F; Avallone A; Maiello E; Cremolini C; Troiani T; Martinelli E; Ciardiello F; Martini G
    Clin Colorectal Cancer; 2022 Jun; 21(2):141-148. PubMed ID: 35101346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nomograms for predicting prognostic value of inflammatory biomarkers in colorectal cancer patients after radical resection.
    Li Y; Jia H; Yu W; Xu Y; Li X; Li Q; Cai S
    Int J Cancer; 2016 Jul; 139(1):220-31. PubMed ID: 26933932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretreatment neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte, and neutrophil/monocyte ratios and outcome in elderly breast cancer patients.
    Losada B; Guerra JA; Malón D; Jara C; Rodriguez L; Del Barco S
    Clin Transl Oncol; 2019 Jul; 21(7):855-863. PubMed ID: 30506134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after resection for hepato-pancreatico-biliary malignancies.
    Spolverato G; Maqsood H; Kim Y; Margonis G; Luo T; Ejaz A; Pawlik TM
    J Surg Oncol; 2015 Jun; 111(7):868-74. PubMed ID: 25865111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer.
    Lozano Martínez AJ; Moreno Cano R; Escobar Páramo S; Salguero Aguilar R; Gonzalez Billalabeitia E; García Fernández R; De La Fuente Muñoz I; Romero Borque A; Porras Martínez M; Lopez Soler F; Cardenas Cánovas E; Ortega Martín I
    Clin Transl Oncol; 2017 Dec; 19(12):1531-1536. PubMed ID: 28718070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative neutrophil-lymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery.
    Zhang Y; Wang L; Liu Y; Wang S; Shang P; Gao Y; Chen X
    Int J Gynecol Cancer; 2014 Sep; 24(7):1319-25. PubMed ID: 25033256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A High Monocyte-to-Lymphocyte Ratio Predicts Poor Prognosis in Patients with Advanced Gallbladder Cancer Receiving Chemotherapy.
    Choi YH; Lee JW; Lee SH; Choi JH; Kang J; Lee BS; Paik WH; Ryu JK; Kim YT
    Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1045-1051. PubMed ID: 30842131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Preoperative Lymphocyte-to-Monocyte Ratio is Prognostic of Clinical Outcomes for Patients with Liver-Only Colorectal Metastases in the Neoadjuvant Setting.
    Neofytou K; Smyth EC; Giakoustidis A; Khan AZ; Williams R; Cunningham D; Mudan S
    Ann Surg Oncol; 2015 Dec; 22(13):4353-62. PubMed ID: 25773876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.
    Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T
    Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.
    Jeong JH; Kim J; Hong YS; Kim D; Kim JE; Kim SY; Kim KP; Yoon YK; Kim D; Chun SM; Park Y; Jang SJ; Kim TW
    Clin Colorectal Cancer; 2017 Sep; 16(3):e147-e152. PubMed ID: 28223103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.